Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-015-1039-y) contains supplementary material, which is available to authorized users.
To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients.
HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module, EQ-5D, and VAS in an observational study over multiple years. All HRQoL measurements per patient were connected and analysed using area under the curve analysis over the entire study duration. The total patient group was compared with the general population, and three groups of CLL patients were described separately, i.e. patients without any active treatment (“watch and wait”), chlorambucil treatment only, and patients with other treatment(s).
HRQoL in the total group of CLL patients was compromised when compared with age- and gender-matched norm scores of the general population. CLL patients scored statistically worse on the VAS and utility score of the EQ-5D, all functioning scales of the EORTC QLQ-C30, and the symptoms of fatigue, dyspnoea, sleeping disturbance, appetite loss, and financial difficulties. In untreated patients, the HRQoL was slightly reduced. In all treatment stages, HRQoL was compromised considerably. Patients treated with chlorambucil only scored worse on the EORTC QLQ-C30 than patients who were treated with other treatments with regard to emotional functioning, cognitive functioning, bruises, uncomfortable stomach, and apathy.
CLL patients differ most from the general population on role functioning, fatigue, concerns about future health, and having not enough energy. Once treatment is indicated, HRQoL becomes considerably compromised. This applies to all treatments, including chlorambucil, which is considered to be a mild treatment.
Altekruse, S. F., Kosary, C. L., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., et al. (Eds.). SEER cancer statistics review, 1975– 2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/. Accessed July 2010.
Cancer Research UK. (2008). Data table: Incidence cases and rates for males, females and persons in the UK, England, Wales, Scotland and Northern Ireland. http://publications.cancerresearchuk.org/cancerstats/statsincidence/dtinccountries.html 2011: 2. Accessed Aug 2013.
Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., & Appelbaum, F. R. (2001). Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 19, 3611–3621. PubMed
Efficace, F., Kemmler, G., Vignetti, M., Mandelli, F., Molica, S., & Holzner, B. (2008). Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trialsâ€”A systematic review to evaluate the added value in supporting clinical decision making. European Journal of Cancer, 44, 1497–1506. CrossRefPubMed
Eichhorst, B. F., Busch, R., Obwandner, T., Kuhn-Hallek, I., Herschbach, P., Hallek, M., & German CLL Study Group. (2007). Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: A study by the German CLL Study Group. Journal of Clinical Oncology, 25, 1722–1731. CrossRefPubMed
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M. J., Bezares, R. F., et al. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. The Lancet, 370, 230–239. CrossRef
Kay, N. E. (2012). Predicting clinical outcome in B-chronic lymphocytic leukemia. In ASCO educational book (pp. 394–398). http://meetinglibrary.asco.org/content/145-114
Holzner, B., Kemmler, G., Kopp, M., Nguyen-Van-Tam, D., Sperner-Unterweger, B., & Greil, R. (2004). Quality of life of patients with chronic lymphocytic leukemia: Results of a longitudinal investigation over 1 yr. European Journal of Hematology, 72, 381–389. CrossRef
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376. CrossRefPubMed
Brooks, R., Rabin, R., & De Charro, F. (Eds.). (2003). The measurement and valuation of health status using EQ-5D: A European perspective; evidence from the EuroQol BIOMED Research Programme (1st ed.). Dordrecht: Kluwer Academic Publishers.
Kind, P., & Macran, S. (2002). Levelling the playing field: Increasing the number of response categories in EQ-5D. In Kind and Macran. York: University of York.
Sprangers, M. A., Cull, A., Groenvold, M., Bjordal, K., Blazeby, J., & Aaronson, N. K. (1998). The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: An update and overview. EORTC Quality of Life Study Group. Quality of Life Research, 7, 291–300. CrossRefPubMed
Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., & on behalf of the EORTC Quality of Life Group. (2001). The EORTC QLQ-C30 scoring manual (3rd ed.). Brussels: European Organisation for Research and Treatment of Cancer.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16, 139–144. PubMed
EORTC. Chronic lymphocytic leukaemia (QLQ-CLL16). http://groups.eortc.be/qol/chronic-lymphocytic-leukaemia-qlq-cll16. Accessed Dec 2013.
Holtzer-Goor, K. M., Bouwmans-Frijters, C. A., Schaafsma, M. R., & Uyl-de Groot, C. A. (2011). A cost of illness and quality of life study in patients with B-cell chronic lymphocytic leukemia (CLL) in the Netherlands. Rotterdam: Erasmus University Rotterdam.
Hallek, M., Fischer, K., Fingerle-Rowson, G., et al. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. The Lancet, 376, 1164–1174. CrossRef
Comprehensive Cancer Centre the Netherlands (IKNL). (2010). www.cijfersoverkanker.nl. Accessed Dec 2013.
Kater, A. P., & van Oers, M. H. (2003). Chronic lymphocytic leukemia: High time for a risk-adapted approach. Nederlands Tijdschrift voor Geneeskunde, 147, 104–109. PubMed
- Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study
K. M. Holtzer-Goor
M. R. Schaafsma
E. F. M. Posthuma
P. C. Huijgens
E. J. M. Mattijssen
W. G. Peters
P. W. Wijermans
S. M. G. J. Daenen
K. G. van der Hem
M. H. J. van Oers
C. A. Uyl-de Groot
- Springer International Publishing